DRP007963 Track Settings
 
Whole genome bisulfite sequencing of colorectal cancer [Metastatic Cancerous Tissue Obtained, Primary Cancerous Tissue]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
DRX239216 
DRX239217 
DRX239218 
DRX239219 
DRX239220 
DRX239221 
DRX239222 
DRX239223 
DRX239224 
DRX239225 
DRX239226 
DRX239227 
DRX239228 
DRX239229 
DRX239230 
DRX239231 
DRX239232 
DRX239233 
DRX239234 
DRX239235 
DRX239236 
DRX239237 
DRX239238 
DRX239239 
DRX239240 
DRX239241 
DRX239242 
DRX239243 
DRX239244 
DRX239245 
DRX239246 
DRX239247 
DRX239248 
DRX239249 
DRX239250 
DRX239251 
experiment
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 DRX239216  HMR  Primary Cancerous Tissue / DRX239216 (HMR)   schema 
hide
 DRX239216  CpG methylation  Primary Cancerous Tissue / DRX239216 (CpG methylation)   schema 
hide
 DRX239217  HMR  Primary Cancerous Tissue / DRX239217 (HMR)   schema 
hide
 DRX239217  CpG methylation  Primary Cancerous Tissue / DRX239217 (CpG methylation)   schema 
hide
 DRX239218  HMR  Primary Cancerous Tissue / DRX239218 (HMR)   schema 
hide
 DRX239218  CpG methylation  Primary Cancerous Tissue / DRX239218 (CpG methylation)   schema 
hide
 DRX239219  HMR  Primary Cancerous Tissue / DRX239219 (HMR)   schema 
hide
 DRX239219  CpG methylation  Primary Cancerous Tissue / DRX239219 (CpG methylation)   schema 
hide
 DRX239220  HMR  Primary Cancerous Tissue / DRX239220 (HMR)   schema 
hide
 DRX239220  CpG methylation  Primary Cancerous Tissue / DRX239220 (CpG methylation)   schema 
hide
 DRX239221  HMR  Primary Cancerous Tissue / DRX239221 (HMR)   schema 
hide
 DRX239221  CpG methylation  Primary Cancerous Tissue / DRX239221 (CpG methylation)   schema 
hide
 DRX239222  HMR  Primary Cancerous Tissue / DRX239222 (HMR)   schema 
hide
 DRX239222  CpG methylation  Primary Cancerous Tissue / DRX239222 (CpG methylation)   schema 
hide
 DRX239223  HMR  Primary Cancerous Tissue / DRX239223 (HMR)   schema 
hide
 DRX239223  CpG methylation  Primary Cancerous Tissue / DRX239223 (CpG methylation)   schema 
hide
 DRX239224  HMR  Primary Cancerous Tissue / DRX239224 (HMR)   schema 
hide
 DRX239224  CpG methylation  Primary Cancerous Tissue / DRX239224 (CpG methylation)   schema 
hide
 DRX239225  HMR  Primary Cancerous Tissue / DRX239225 (HMR)   schema 
hide
 DRX239225  CpG methylation  Primary Cancerous Tissue / DRX239225 (CpG methylation)   schema 
hide
 DRX239232  HMR  Primary Cancerous Tissue / DRX239232 (HMR)   schema 
hide
 DRX239226  CpG methylation  Primary Cancerous Tissue / DRX239226 (CpG methylation)   schema 
hide
 DRX239233  HMR  Primary Cancerous Tissue / DRX239233 (HMR)   schema 
hide
 DRX239227  CpG methylation  Primary Cancerous Tissue / DRX239227 (CpG methylation)   schema 
hide
 DRX239234  HMR  Metastatic Cancerous Tissue Obtained / DRX239234 (HMR)   schema 
hide
 DRX239228  CpG methylation  Primary Cancerous Tissue / DRX239228 (CpG methylation)   schema 
hide
 DRX239235  HMR  Metastatic Cancerous Tissue Obtained / DRX239235 (HMR)   schema 
hide
 DRX239229  CpG methylation  Primary Cancerous Tissue / DRX239229 (CpG methylation)   schema 
hide
 DRX239236  HMR  Metastatic Cancerous Tissue Obtained / DRX239236 (HMR)   schema 
hide
 DRX239230  CpG methylation  Primary Cancerous Tissue / DRX239230 (CpG methylation)   schema 
hide
 DRX239237  HMR  Metastatic Cancerous Tissue Obtained / DRX239237 (HMR)   schema 
hide
 DRX239231  CpG methylation  Primary Cancerous Tissue / DRX239231 (CpG methylation)   schema 
hide
 DRX239238  HMR  Metastatic Cancerous Tissue Obtained / DRX239238 (HMR)   schema 
hide
 DRX239232  CpG methylation  Primary Cancerous Tissue / DRX239232 (CpG methylation)   schema 
hide
 DRX239239  HMR  Metastatic Cancerous Tissue Obtained / DRX239239 (HMR)   schema 
hide
 DRX239233  CpG methylation  Primary Cancerous Tissue / DRX239233 (CpG methylation)   schema 
hide
 DRX239242  HMR  Metastatic Cancerous Tissue Obtained / DRX239242 (HMR)   schema 
hide
 DRX239234  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239234 (CpG methylation)   schema 
hide
 DRX239243  HMR  Metastatic Cancerous Tissue Obtained / DRX239243 (HMR)   schema 
hide
 DRX239235  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239235 (CpG methylation)   schema 
hide
 DRX239244  HMR  Metastatic Cancerous Tissue Obtained / DRX239244 (HMR)   schema 
hide
 DRX239236  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239236 (CpG methylation)   schema 
hide
 DRX239245  HMR  Metastatic Cancerous Tissue Obtained / DRX239245 (HMR)   schema 
hide
 DRX239237  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239237 (CpG methylation)   schema 
hide
 DRX239238  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239238 (CpG methylation)   schema 
hide
 DRX239239  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239239 (CpG methylation)   schema 
hide
 DRX239240  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239240 (CpG methylation)   schema 
hide
 DRX239241  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239241 (CpG methylation)   schema 
hide
 DRX239242  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239242 (CpG methylation)   schema 
hide
 DRX239243  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239243 (CpG methylation)   schema 
hide
 DRX239244  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239244 (CpG methylation)   schema 
hide
 DRX239245  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239245 (CpG methylation)   schema 
hide
 DRX239246  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239246 (CpG methylation)   schema 
hide
 DRX239247  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239247 (CpG methylation)   schema 
hide
 DRX239248  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239248 (CpG methylation)   schema 
hide
 DRX239249  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239249 (CpG methylation)   schema 
hide
 DRX239250  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239250 (CpG methylation)   schema 
hide
 DRX239251  CpG methylation  Metastatic Cancerous Tissue Obtained / DRX239251 (CpG methylation)   schema 
    

Study title: Whole genome bisulfite sequencing of colorectal cancer
SRA: DRP007963
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
DRX239216 Primary Cancerous Tissue 0.725 10.8 60065 1274.0 3607 1251.8 1820 21423.3 0.988 HiSeq X Ten paired end sequencing of SAMD00251177
DRX239217 Primary Cancerous Tissue 0.738 5.1 44473 1434.8 1068 1082.8 623 34940.1 0.987 HiSeq X Ten paired end sequencing of SAMD00251178
DRX239218 Primary Cancerous Tissue 0.689 4.5 32451 2095.3 1719 1188.6 768 1433521.9 0.988 HiSeq X Ten paired end sequencing of SAMD00251179
DRX239219 Primary Cancerous Tissue 0.703 4.7 31521 1999.8 1745 1197.5 822 1361482.9 0.988 HiSeq X Ten paired end sequencing of SAMD00251180
DRX239220 Primary Cancerous Tissue 0.636 9.1 47765 2377.8 2233 1152.7 798 1452744.7 0.988 HiSeq X Ten paired end sequencing of SAMD00251181
DRX239221 Primary Cancerous Tissue 0.651 4.1 36525 2554.6 458 1144.6 698 1711046.1 0.987 HiSeq X Ten paired end sequencing of SAMD00251182
DRX239222 Primary Cancerous Tissue 0.648 10.9 46450 3753.2 3316 1217.0 1200 975592.8 0.988 HiSeq X Ten paired end sequencing of SAMD00251183
DRX239223 Primary Cancerous Tissue 0.662 5.5 38546 3761.3 1268 1164.1 892 1258554.7 0.988 HiSeq X Ten paired end sequencing of SAMD00251184
DRX239224 Primary Cancerous Tissue 0.650 10.3 50612 2355.9 3169 1162.1 1405 752348.4 0.988 HiSeq X Ten paired end sequencing of SAMD00251185
DRX239225 Primary Cancerous Tissue 0.661 6.4 41575 2431.5 1855 1152.0 1144 908771.1 0.988 HiSeq X Ten paired end sequencing of SAMD00251186
DRX239226 Primary Cancerous Tissue 0.593 13.5 40941 6326.1 3301 1200.9 884 1383367.6 0.988 HiSeq X Ten paired end sequencing of SAMD00251187
DRX239227 Primary Cancerous Tissue 0.605 6.1 34964 6628.1 1263 1069.9 697 1663606.6 0.988 HiSeq X Ten paired end sequencing of SAMD00251188
DRX239228 Primary Cancerous Tissue 0.549 13.9 65346 11942.2 3064 1151.4 2792 442867.7 0.988 HiSeq X Ten paired end sequencing of SAMD00251189
DRX239229 Primary Cancerous Tissue 0.563 8.9 51301 13803.8 1974 1132.1 2323 528559.6 0.987 HiSeq X Ten paired end sequencing of SAMD00251190
DRX239230 Primary Cancerous Tissue 0.499 13.2 22881 26307.1 2430 1060.2 2339 697107.2 0.988 HiSeq X Ten paired end sequencing of SAMD00251191
DRX239231 Primary Cancerous Tissue 0.518 6.9 12494 31679.1 1209 1062.1 1917 829818.5 0.988 HiSeq X Ten paired end sequencing of SAMD00251192
DRX239232 Primary Cancerous Tissue 0.642 13.1 54008 3264.0 4052 1131.0 964 1197917.6 0.987 HiSeq X Ten paired end sequencing of SAMD00251193
DRX239233 Primary Cancerous Tissue 0.656 5.7 41879 3200.4 1553 1121.9 683 1553364.4 0.988 HiSeq X Ten paired end sequencing of SAMD00251194
DRX239234 Metastatic Cancerous Tissue Obtained 0.727 7.2 38960 1235.8 3010 1276.1 1255 14614.9 0.987 HiSeq X Ten paired end sequencing of SAMD00251195
DRX239235 Metastatic Cancerous Tissue Obtained 0.730 4.1 33194 1358.7 1288 1240.6 399 30257.9 0.986 HiSeq X Ten paired end sequencing of SAMD00251196
DRX239236 Metastatic Cancerous Tissue Obtained 0.678 5.6 30836 1430.0 1157 1100.2 361 33284.2 0.983 HiSeq X Ten paired end sequencing of SAMD00251197
DRX239237 Metastatic Cancerous Tissue Obtained 0.679 4.8 29762 1524.7 831 1068.0 368 30553.4 0.982 HiSeq X Ten paired end sequencing of SAMD00251198
DRX239238 Metastatic Cancerous Tissue Obtained 0.644 8.5 45105 2489.6 1015 1079.8 857 1367719.2 0.984 HiSeq X Ten paired end sequencing of SAMD00251199
DRX239239 Metastatic Cancerous Tissue Obtained 0.648 2.6 29116 2950.4 22 1236.9 492 2173881.9 0.984 HiSeq X Ten paired end sequencing of SAMD00251200
DRX239240 Metastatic Cancerous Tissue Obtained 0.632 10.6 49727 4151.4 2501 1176.4 1223 926706.7 0.986 HiSeq X Ten paired end sequencing of SAMD00251201
DRX239241 Metastatic Cancerous Tissue Obtained 0.636 4.4 35794 4352.3 481 1049.6 818 1325702.4 0.986 HiSeq X Ten paired end sequencing of SAMD00251202
DRX239242 Metastatic Cancerous Tissue Obtained 0.679 8.8 33995 1340.2 751 907.7 1242 23669.1 0.975 HiSeq X Ten paired end sequencing of SAMD00251203
DRX239243 Metastatic Cancerous Tissue Obtained 0.685 3.1 28155 1762.9 32 995.2 331 51113.5 0.975 HiSeq X Ten paired end sequencing of SAMD00251204
DRX239244 Metastatic Cancerous Tissue Obtained 0.665 8.0 35272 1441.8 3566 1216.1 944 1231938.6 0.985 HiSeq X Ten paired end sequencing of SAMD00251205
DRX239245 Metastatic Cancerous Tissue Obtained 0.668 6.1 33034 1569.2 2384 1196.1 659 1667807.5 0.984 HiSeq X Ten paired end sequencing of SAMD00251206
DRX239246 Metastatic Cancerous Tissue Obtained 0.561 8.7 47477 14730.3 2165 1110.2 2427 521914.0 0.986 HiSeq X Ten paired end sequencing of SAMD00251207
DRX239247 Metastatic Cancerous Tissue Obtained 0.575 7.8 46587 14667.9 1855 1100.7 2301 547594.1 0.987 HiSeq X Ten paired end sequencing of SAMD00251208
DRX239248 Metastatic Cancerous Tissue Obtained 0.473 10.8 21570 31709.3 1386 1063.7 2973 551362.9 0.988 HiSeq X Ten paired end sequencing of SAMD00251209
DRX239249 Metastatic Cancerous Tissue Obtained 0.481 5.0 6779 50439.7 276 1053.5 2294 699690.7 0.988 HiSeq X Ten paired end sequencing of SAMD00251210
DRX239250 Metastatic Cancerous Tissue Obtained 0.553 9.8 38886 10039.8 560 995.9 1345 905810.7 0.980 HiSeq X Ten paired end sequencing of SAMD00251211
DRX239251 Metastatic Cancerous Tissue Obtained 0.558 3.6 26762 9474.9 56 1012.7 975 1225155.8 0.980 HiSeq X Ten paired end sequencing of SAMD00251212

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.